HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joanna C Neill Selected Research

Schizophrenia (Dementia Praecox)

1/2023Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172.
1/2022Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study.
1/2022The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia.
4/2021Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856.
1/2021Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
10/2019Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory.
11/2018NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.
1/2017Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation.
11/2016Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine.
10/2016Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joanna C Neill Research Topics

Disease

24Schizophrenia (Dementia Praecox)
01/2023 - 03/2002
8Cognitive Dysfunction
01/2022 - 09/2010
4Weight Gain
11/2009 - 03/2002
2Infections
01/2023 - 12/2022
2Psychotic Disorders (Schizoaffective Disorder)
01/2021 - 01/2016
2Body Weight (Weight, Body)
01/2019 - 11/2009
2Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
04/2015 - 08/2014
1Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/2023
1Encephalitis (Encephalitis, Rasmussen)
01/2023
1Inflammation (Inflammations)
01/2023
1Necrosis
01/2023
1Fetal Weight
12/2022
1Autistic Disorder (Autism)
01/2022
1Treatment-Resistant Schizophrenia
01/2021
1Memory Disorders (Memory Loss)
01/2018
1Neoplasms (Cancer)
05/2015
1Traumatic Brain Injuries (Traumatic Brain Injury)
05/2015
1Alzheimer Disease (Alzheimer's Disease)
09/2010

Drug/Important Bio-Agent (IBA)

13Phencyclidine (Angel Dust)IBA
01/2022 - 03/2008
8Antipsychotic Agents (Antipsychotics)IBA
01/2022 - 03/2002
4N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
11/2018 - 05/2008
3Olanzapine (Zyprexa)FDA Link
11/2009 - 03/2002
2Poly I-CIBA
01/2023 - 12/2022
2N- cyclobutyl- 6- ((3- fluorophenyl)ethynyl)nicotinamideIBA
01/2023 - 01/2022
2VU0409551IBA
01/2023 - 01/2022
2CytokinesIBA
01/2023 - 12/2022
2Interleukin-6 (Interleukin 6)IBA
01/2022 - 01/2019
2Dizocilpine Maleate (Dizocilpine)IBA
11/2018 - 12/2010
2KetamineFDA LinkGeneric
11/2018 - 12/2010
2Dopamine (Intropin)FDA LinkGeneric
01/2017 - 04/2015
2Neurotransmitter Agents (Neurotransmitter)IBA
11/2016 - 01/2004
2gamma-Aminobutyric Acid (GABA)IBA
11/2016 - 01/2004
2ParvalbuminsIBA
11/2016 - 01/2016
2Calcium-Binding ProteinsIBA
11/2016 - 01/2004
2Clozapine (Clozaril)FDA LinkGeneric
11/2009 - 03/2002
1Antidepressive Agents (Antidepressants)IBA
01/2023
1Amino AcidsFDA Link
12/2022
1SEP-363856IBA
04/2021
1PyridoxamineIBA
10/2019
1Amyloid (Amyloid Fibrils)IBA
01/2018
12-(3',4',5',6'-tetrahydro-2'H-(2,4') bipyridinyl-1'-yl)-N-m-tolyl-acetamideIBA
04/2015
1catechol (pyrocatechol)IBA
04/2015
1TransferasesIBA
04/2015
1Tolcapone (Tasmar)FDA Link
04/2015
1Dopamine D4 Receptors (Dopamine D4 Receptor)IBA
04/2015
1N- ((4- (2- cyanophenyl)- 1- piperazinyl)methyl)- 3- methylbenzamideIBA
06/2011
1Brain-Derived Neurotrophic Factor (BDNF)IBA
03/2011
1Nerve Growth Factors (Neurotrophins)IBA
03/2011
1N-Methylaspartate (NMDA)IBA
12/2010
1(2- (6- fluoro- 1H- indol- 3- yl)- ethyl)- (3- (2,2,3,3- tetrafluoropropoxy)benzyl)amineIBA
09/2010
18- (4- methylpiperazin- 1- yl)- 3- phenylsulfonylquinolineIBA
09/2010
1Histamine H1 AntagonistsIBA
11/2009
1SB 243213IBA
11/2009
1Histamine H1 Receptors (Histamine H1 Receptor)IBA
11/2009
15-HT2C Serotonin ReceptorIBA
11/2009
1Haloperidol (Haldol)FDA LinkGeneric
11/2009
1Serotonin 5-HT2 Receptor AntagonistsIBA
11/2009
1Pyrilamine (Mepyramine)FDA Link
11/2009
1Serotonin ReceptorsIBA
10/2009
1Aripiprazole (Abilify)FDA Link
08/2008
1Fluoxetine (Prozac)FDA LinkGeneric
08/2008
1ziprasidone (Geodon)FDA Link
11/2004
1CalbindinsIBA
01/2004
1Calbindin 2IBA
01/2004

Therapy/Procedure

3Drug Therapy (Chemotherapy)
05/2015 - 09/2010
2Therapeutics
10/2019 - 12/2010
1Drug Tapering
01/2021
1Secondary Prevention
01/2021
1Injections
11/2009